• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Copyright compliance in the life sciences industry
race-uphill-sand-dune
31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   The Otsuka v Sun Pharma appeal could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in Australia.
Careers
Vinson & Elkins grows West Coast patent and trade secrets bench
1 July 2026   A first-chair trial lawyer with two decades in high-stakes patent and trade secret disputes brings experience across medical devices, biologics, and pharmaceuticals, alongside a broader technology-focused practice.
Americas
Will Mounjaro and Zepbound get their first US generic rival?
30 June 2026   Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.


Editor's picks

Pfizer’s US Paxlovid patent fight turns on a single error
Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026

Editor's picks

Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026

More features

‘Blatant imitation’: Indian court blocks copycat pharma branding
Kirkland & Ellis adds leading barrister in London
Kilpatrick adds tech patent litigator and China expert to Chicago office
Litigator from Brown Rudnick moves firms to chair practice
Patent office fee increases: What applicants must know
IndiaMart v CDSCO: A test of intermediary liability
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Arnold & Porter adds tech litigator in San Francisco

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin